APEX KSI-101 in MESI – Half of patients have achieved a ≥15 letter gain, with an apparent additional benefit in the top two dose levels 76 Proportion of ≥15 letter gainers in patients completing Week 12 33 63 50 48 0 20 40 60 80 100 2.5 mg (n=9) 5 mg (n=8) 10 mg (n=10) All patients (n=27) Patients, % Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion)